I'm LongbridgeAI, I can summarize articles.Revenue grew 21.1% year-over-year, led by oncology product sales and FX gains, while core operating profit rose 6.2%. Full-year revenue guidance was raised, but profit attributable to owners declined 19.7% due to higher taxes and expenses. Major oncology approvals and a phased divestiture of the healthcare unit were key developments.Original document: Daiichi Sankyo Company, Limited [4568] Interim report — Jul. 31 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Revenue grew 21.1% year-over-year, led by oncology product sales and FX gains, while core operating profit rose 6.2%. Full-year revenue guidance was raised, but profit attributable to owners declined 19.7% due to higher taxes and expenses. Major oncology approvals and a phased divestiture of the healthcare unit were key developments.
Original document: Daiichi Sankyo Company, Limited [4568] Interim report — Jul. 31 2026